WallStreetZenWallStreetZen

NYSE: NVO
Novo Nordisk A S Stock

Overview
ForecastEarningsDividendOwnership
$125.79-0.37 (-0.29%)
Updated Apr 25, 2024
NVO Price
$125.79
Fair Value Price
N/A
Market Cap
$567.31B
52 Week Low
$75.56
52 Week High
$138.28
P/E
46.28x
P/B
36.57x
P/S
13.71x
PEG
9.72x
Dividend Yield
1.09%
Revenue
$33.81B
Earnings
$12.40B
Gross Margin
84.6%
Operating Margin
45.23%
Profit Margin
36%
Debt to Equity
1.95
Operating Cash Flow
$16B
Beta
0.55
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A

NVO Overview

Novo Nordisk A/S manufactures pharmaceutical products. Its Diabetes and Obesity Care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. Novo Nordisk was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Zen Score

–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NVO scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NVO ($125.79) is trading above its intrinsic value of $19.45, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NVO is poor value based on its earnings relative to its share price (46.28x), compared to the US market average (40.97x)
P/E vs Market Valuation
NVO is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more NVO due diligence checks available for Premium users.

Be the first to know about important NVO news, forecast changes, insider trades & much more!

NVO News

Valuation

NVO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
46.28x
Industry
15.41x
Market
40.97x
NVO is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
NVO is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

NVO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
36.57x
Industry
5.8x
NVO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NVO price to earnings growth (PEG)

For valuing profitable companies with growth potential
NVO is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

NVO's financial health

Profit margin

Revenue
$9.8B
Net Income
$3.3B
Profit Margin
33.3%
NVO's Earnings (EBIT) of $15.29B... subscribe to Premium to read more.
Interest Coverage Financials
NVO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$46.6B
Liabilities
$30.8B
Debt to equity
1.95
NVO's short-term liabilities ($24.70B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NVO's short-term assets ($20.33B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NVO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NVO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$5.5B
Investing
-$4.9B
Financing
-$2.8B
NVO's operating cash flow ($15.85B)... subscribe to Premium to read more.
Debt Coverage Financials

NVO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
NVO$567.31B-0.29%46.28x36.57x
VRTX$102.73B-0.76%28.31x5.84x
REGN$97.76B-1.75%24.04x3.76x
MRNA$40.57B-2.45%-8.61x2.93x
ARGX$21.82B-1.71%-65.72x4.90x
View Top Biotech Stocks

Novo Nordisk A S Stock FAQ

What is Novo Nordisk A S's quote symbol?

(NYSE: NVO) Novo Nordisk A S trades on the NYSE under the ticker symbol NVO. Novo Nordisk A S stock quotes can also be displayed as NYSE: NVO.

If you're new to stock investing, here's how to buy Novo Nordisk A S stock.

What is the 52 week high and low for Novo Nordisk A S (NYSE: NVO)?

(NYSE: NVO) Novo Nordisk A S's 52-week high was $138.28, and its 52-week low was $75.56. It is currently -9.03% from its 52-week high and 66.48% from its 52-week low.

How much is Novo Nordisk A S stock worth today?

(NYSE: NVO) Novo Nordisk A S currently has 4,510,000,000 outstanding shares. With Novo Nordisk A S stock trading at $125.79 per share, the total value of Novo Nordisk A S stock (market capitalization) is $567.31B.

Novo Nordisk A S stock was originally listed at a price of $1.44 in Dec 31, 1997. If you had invested in Novo Nordisk A S stock at $1.44, your return over the last 26 years would have been 8,617.26%, for an annualized return of 18.75% (not including any dividends or dividend reinvestments).

How much is Novo Nordisk A S's stock price per share?

(NYSE: NVO) Novo Nordisk A S stock price per share is $125.79 today (as of Apr 25, 2024).

What is Novo Nordisk A S's Market Cap?

(NYSE: NVO) Novo Nordisk A S's market cap is $567.31B, as of Apr 27, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Novo Nordisk A S's market cap is calculated by multiplying NVO's current stock price of $125.79 by NVO's total outstanding shares of 4,510,000,000.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.